This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Lysine & hydroxylysine metabolism disorders — Hyperlysinemia / Hydroxylysinemia / AASS deficiency라이신 및 하이드록시라이신 대사장애

Contents and key points
ItemDetails
A. Classification codesICD-10: E72.3 | Special Copayment Reduction: V117
B. SynonymsHyperlysinemia (Familial hyperlysinemia), Disorders of lysine metabolism, AASS deficiency (α-aminoadipic semialdehyde synthase deficiency), Hydroxylysinemia, AGXT2L1 deficiency, Pipecolic acidemia, α-Ketoadipic acidemia
C. Adult onsetLikelihood of first diagnosis in adulthood high (hyperlysinemia, pipecolic acidemia) — most cases of hyperlysinemia are asymptomatic or have nonspecific symptoms and remain undiagnosed into adulthood. Peroxisomal disorders associated with pipecolic acidemia can present with neurological symptoms in adulthood. α-Ketoadipic acidemia and hydroxylysinemia are rare and possible at any age.
1. History1964, first description of hyperlysinemia by Ghadimi et al. → identification of the AASS gene and enzyme (1970s–2000s) → discovery of the peroxisomal β-oxidation pathway for pipecolic acid → increase in incidental detection in the tandem MS/MS era → debate over clinical significance ongoing.
2. CausesEnzyme deficiency in the lysine degradation pathway (saccharopine pathway or pipecolic acid pathway). AASS (α-aminoadipic semialdehyde synthase) deficiency → hyperlysinemia type I (block of the saccharopine pathway). AGXT2L1 deficiency → hydroxylysinemia. Pipecolic acidemia results from deficiency of peroxisome- and mitochondria-related enzymes such as AMACR and L2HGDH. Autosomal recessive.
3. GeneticsAASS gene (7q31.32): responsible for two enzyme activities (LKR+SDH). Autosomal recessive. AGXT2L1 (2q37): hydroxylysine degradation. PIPOX: pipecolic acid oxidase. Multiple genes cooperate in the related pathways.
4. General epidemiologyHyperlysinemia: about 1 in 100,000–500,000 at newborn screening (estimate before tandem MS/MS). Hydroxylysinemia, pipecolic acidemia, α-ketoadipic acidemia: very rare (1 in several million). Actual prevalence is unclear because clinical significance is under debate.
5. PathophysiologyLysine is an essential amino acid with various functions, including pyridine and carnitine synthesis and collagen cross-linking. When the degradation pathway is blocked, lysine, saccharopine, pipecolic acid, hydroxylysine, and others accumulate. For most of these metabolic abnormalities the toxic mechanism is unclear. Pipecolic acidemia is associated with peroxisomal dysfunction.
6. SymptomsHyperlysinemia: mostly asymptomatic. Intellectual disability and seizures in some (causality disputed). Hydroxylysinemia: asymptomatic. Pipecolic acidemia: differentiation from peroxisomal disorders such as Zellweger needed before recurrent fever in the liver. α-Ketoadipic acidemia: intellectual disability, hypotonia.
7. SignsElevated plasma lysine. Urinary excretion of lysine, saccharopine, and pipecolic acid. Elevated plasma hydroxylysine (hydroxylysinemia). Elevated plasma/urine α-ketoadipic acid. Peroxisomal function tests (long-chain fatty acids, phytanic acid, etc.).
8. ScreeningNewborn tandem MS/MS: hyperlysinemia is sometimes detected incidentally by elevated blood lysine. Urine amino acid chromatography (lysine, saccharopine, pipecolic acid). Plasma amino acid analysis.
9. DiagnosisPlasma amino acids (quantification of lysine, hydroxylysine, saccharopine), urine organic acids (α-ketoadipic acid, pipecolic acid), AASS·AGXT2L1·PIPOX gene panel, measurement of enzyme activity in skin fibroblasts or liver. Peroxisomal biochemical tests (phytanic acid, long-chain fatty acids) performed in parallel.
10. TreatmentMostly no specific treatment (asymptomatic hyperlysinemia, hydroxylysinemia). When symptomatic: low-lysine diet (insufficient evidence). α-Ketoadipic acidemia: low-protein diet, trial of riboflavin. Pipecolic acidemia: management depends on whether a peroxisomal disorder is present. Seizures: standard anticonvulsants.
11. PrognosisHyperlysinemia and hydroxylysinemia: mostly good prognosis (benign course). Pipecolic acidemia: prognosis determined by the accompanying peroxisomal disorder. α-Ketoadipic acidemia: neurodevelopmental impairment may persist, but natural history data are lacking.
12. PreventionPeriodic follow-up when detected incidentally after newborn screening. Specialist metabolic follow-up when accompanied by a peroxisomal disorder. Genetic counseling. Restriction of excessive lysine intake during pregnancy (evidence unclear).
13. ReferencesSaudubray JM et al. Inborn Metabolic Diseases. 6th ed. 2016 and 9 others

1. History

The clinical history of lysine and hydroxylysine metabolism disorders begins with the first description of hyperlysinemia. In 1964, Ghadimi, Berthling, and colleagues first described a patient with intellectual disability and markedly elevated lysine in urine and plasma, and hyperlysinemia came to be recognized as a clinical disease. Initially, excessive lysine accumulation was presumed to be causally related to intellectual disability, but later studies presented strong evidence refuting a causal relationship between hyperlysinemia itself and intellectual disability.

In the 1970s it was shown that lysine is metabolized through two degradation pathways, the saccharopine pathway and the pipecolic acid pathway. The saccharopine pathway proceeds mainly in the liver and is initiated by α-aminoadipic semialdehyde synthase (AASS). AASS is a bifunctional enzyme whose single protein carries both lysine-ketoglutarate reductase (LKR) and saccharopine dehydrogenase (SDH) enzyme activities. Deficiency of LKR activity causes hyperlysinemia (no saccharopine accumulation, hyperlysinemia type I), and SDH deficiency causes hypersaccharopinemia (saccharopinuria, hyperlysinemia type II). The AASS gene was cloned on chromosome 7 (7q31.32) in the early 2000s.

The pipecolic acid pathway proceeds in the brain and in various tissues throughout the body, metabolizing lysine via pipecolic acid to L-2-hydroxyglutaric acid. Pipecolic acid is degraded in peroxisomes by pipecolic acid oxidase (PIPOX). Pipecolic acidemia occurs on its own but is also a marker that appears secondarily in peroxisome biogenesis disorders (Zellweger syndrome spectrum). Since the 2000s, the relationship between L-2-hydroxyglutaric aciduria (L2HGA) and the AASS pathway has been clarified. Hydroxylysinemia due to deficiency in the hydroxylysine degradation pathway (AGXT2L1 gene) is very rare, and its clinical significance is unclear. As the expansion of tandem MS/MS-based newborn screening has increased the frequency of incidental detection of lysine-related metabolic abnormalities, debate continues over the clinical significance of these disorders and the need for treatment.


2. Causes

Lysine and hydroxylysine metabolism disorders are a heterogeneous group of diseases caused by deficiency of various enzymes in the degradation pathways of lysine and hydroxylysine. Lysine is an essential amino acid that is used for protein synthesis or degraded to provide energy and carbon skeletons.

Main pathways of lysine degradation: (1) Saccharopine pathway: proceeds mainly in the liver. Lysine + α-ketoglutarate → saccharopine [catalyzed by LKR] → α-aminoadipic-δ-semialdehyde (AASA) + glutamate [catalyzed by SDH] → α-aminoadipic acid → α-ketoadipic acid → glutaryl-CoA (where GCDH is involved, joining the GA1 pathway) → acetyl-CoA. (2) Pipecolic acid pathway: proceeds in the brain and several tissues. Lysine → piperidine-2-carboxylic acid → pipecolic acid → degraded by PIPOX in peroxisomes → joins the saccharopine pathway.

Main deficiency disorders: ① AASS deficiency (AASS gene, 7q31.32): isolated LKR deficiency causes hyperlysinemia type I (lysine accumulation, normal saccharopine), and isolated SDH deficiency causes hypersaccharopinemia/hyperlysinemia type II (simultaneous accumulation of lysine and saccharopine). Autosomal recessive. ② AGXT2L1 deficiency (AGXT2L1 gene, 2q37): deficiency of the hydroxylysine-degrading enzyme (a functional equivalent of 4-hydroxy-L-glutamate aldolase) → hydroxylysinemia. Autosomal recessive. A very rare disease. ③ Pipecolic acidemia (variants in PIPOX or related genes): reduced pipecolic acid oxidation → pipecolic acid accumulation. Occurs alone or as part of a peroxisomal disorder. ④ α-Ketoadipic acidemia (DHTKD1 gene or related): α-ketoadipic acid dehydrogenase deficiency → accumulation of α-ketoadipic acid and α-aminoadipic acid. Block of the common pathway for lysine, tryptophan, and hydroxylysine degradation. Autosomal recessive.


3. Genetics

The molecular genetic features of the main genes involved in lysine and hydroxylysine metabolism are as follows.

AASS gene (7q31.32): the AASS gene encodes α-aminoadipic semialdehyde synthase, and this single protein contains two enzyme activity domains, LKR (lysine-ketoglutarate reductase, amino acids 42–52) and SDH (saccharopine dehydrogenase). Variants in the LKR domain cause hyperlysinemia type I, and variants in the SDH domain cause hypersaccharopinemia/type II. Variants affecting the whole AASS gene affect both activities, so lysine and saccharopine rise simultaneously. Dozens of variants have been reported to date, the majority being missense variants. Autosomal recessive inheritance. Given the clinically asymptomatic course of hyperlysinemia, the carrier frequency of variants may be higher than expected.

AGXT2L1 gene (2q37.3): encodes an enzyme of the hydroxylysine degradation pathway, and its deficiency causes hydroxylysinemia. Hydroxylysine is produced mainly by hydroxylation in proteins such as collagen, and small amounts are normally excreted in the urine. Hydroxylysinemia is regarded as a benign metabolic abnormality without clinical symptoms. It is a very rare disease, and the number of clinical reports is extremely limited.

PIPOX gene (17q11.2): encodes pipecolic acid oxidase, which degrades pipecolic acid in peroxisomes. Isolated pipecolic acidemia due to PIPOX deficiency is extremely rare. Because elevated pipecolic acid also appears secondarily in peroxisome biogenesis disorders (variants in the PEX gene family), peroxisomal spectrum disorders (Zellweger syndrome, RCDP, etc.) must be ruled out first when pipecolic acidemia is found. Isolated PIPOX deficiency is considered only after peroxisomal disorders have been excluded.

DHTKD1 gene (10p14): encodes the E1α subunit of α-ketoadipic acid dehydrogenase, and its deficiency causes excessive urinary excretion of α-ketoadipic acid and α-aminoadipic acid (α-ketoadipic acidemia). It lies in the common terminal pathway of lysine, tryptophan, and hydroxylysine degradation (downstream of the saccharopine pathway). DHTKD1 variants have also attracted attention because an association with Charcot-Marie-Tooth (CMT)-related peripheral neuropathy has been reported.


4. General epidemiology

The incidence of lysine and hydroxylysine metabolism disorders varies by individual disorder, and most are very rare.

Hyperlysinemia (AASS deficiency): incidence is difficult to estimate, but cases are sometimes detected incidentally by elevated blood lysine on newborn tandem MS/MS screening. The estimated frequency based on past case reports is about 1 in 100,000–500,000, but because many patients are clinically asymptomatic, the actual frequency may be higher. Hypersaccharopinemia (hyperlysinemia type II) is also rarely reported.

Hydroxylysinemia: an extremely rare metabolic abnormality with only a few dozen cases reported worldwide. Because most cases have no clinical symptoms, it often goes undiagnosed.

Pipecolic acidemia: isolated pipecolic acidemia (PIPOX deficiency or isolated pipecolic acid pathway disorder) is very rare, with no more than a few dozen cases reported. When elevated pipecolic acid is found clinically, peroxisomal spectrum disorders (Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease, etc.) must be ruled out first. In this group of peroxisomal disorders, elevated pipecolic acid is common and accompanied by a more severe clinical course.

α-Ketoadipic acidemia: very rare, with only a few dozen patients reported worldwide. Clinical symptoms such as intellectual disability, hypotonia, and delayed language development are accompanied by excessive urinary excretion of α-ketoadipic acid and α-aminoadipic acid. Data on incidence and molecular epidemiology in Korea are very limited.

The clinical significance of these disorders remains controversial. Long-term follow-up studies of patients with hyperlysinemia detected incidentally on newborn screening have mostly concluded that the evidence supporting a causal relationship between lysine levels themselves and neurodevelopmental abnormalities is weak. When clinical significance is unclear, observation and monitoring of the course after diagnosis are recommended.


5. Pathophysiology

The pathophysiology of lysine and hydroxylysine metabolism disorders varies with the deficient enzyme, and some aspects remain unclear.

Mechanism of hyperlysinemia (AASS deficiency): in LKR deficiency of AASS, lysine cannot be converted to saccharopine and accumulates in the blood. However, whether excessive lysine accumulation is actually toxic is disputed. Because lysine binds to lysine receptors (NMDA receptor co-inhibitor) and modulates glutamate neurotransmission, the possibility that hyperlysinemia affects this system has been raised. However, the fact that most patients with hyperlysinemia are clinically asymptomatic suggests that the toxicity of lysine itself is minimal. The current mainstream view is that the intellectual disability mistaken for a causal effect in early reports was most likely an independent neurodevelopmental disorder unrelated to AASS deficiency.

Mechanism of α-ketoadipic acidemia: deficiency of DHTKD1 (or a related enzyme) leads to accumulation of α-ketoadipic acid and α-aminoadipic acid. It has been suggested that these compounds may be directly toxic to neurons or may inhibit mitochondrial energy metabolism. Oxidative stress and mitochondrial dysfunction may contribute to the pathophysiology. However, supporting data are limited, making it difficult to draw firm conclusions.

Mechanism of pipecolic acidemia: possible neurotoxicity of pipecolic acid itself has been suggested in isolated pipecolic acidemia, but evidence for a toxic mechanism is still insufficient. When elevated pipecolic acid serves as a marker of a peroxisomal disorder, the actual neurological damage results from abnormalities of peroxisomal function as a whole. Reduced peroxisomal functions such as β-oxidation of long-chain fatty acids, plasmalogen synthesis, and α-oxidation of phytanic acid cause widespread neurological damage.

Mechanism of hydroxylysinemia: no toxic mechanism is known to date even when hydroxylysine accumulates, and it is clinically asymptomatic. Hydroxylysine plays an important role in stabilizing collagen, but there is no evidence that its accumulation itself affects collagen structure. It is regarded as an incidental finding with a benign course.


6. Symptoms

The clinical symptoms of lysine and hydroxylysine metabolism disorders vary by disorder, and most are clinically asymptomatic or show nonspecific symptoms.

Hyperlysinemia (AASS deficiency): most cases of hyperlysinemia have no clinical symptoms. Most are discovered incidentally on tandem MS/MS newborn screening or during testing for other conditions. In the past it was reported to be associated with intellectual disability, seizures, hypotonia, and behavioral disorders, but the prevailing view now is that these clinical findings are not caused by hyperlysinemia itself but are most likely accompanying independent neurodevelopmental disorders. Macrocephaly has been reported in some patients, but causality is unclear. Hyperlysinemia is currently increasingly regarded as a benign metabolic abnormality.

Hypersaccharopinemia (hyperlysinemia type II, SDH deficiency): likewise, most cases have no or mild clinical symptoms. It is biochemically characterized by elevation of both lysine and saccharopine. Intellectual disability and motor developmental delay have rarely been reported, but causality is unclear.

Hydroxylysinemia: it is typically free of clinical symptoms. There are extremely few reports worldwide, and even when symptoms are present, as with hyperlysinemia, they are likely not lysine-related.

Pipecolic acidemia: neurodevelopmental impairment (intellectual disability, seizures, hypotonia) has been reported in isolated pipecolic acidemia. However, when elevated pipecolic acid accompanies a peroxisomal spectrum disorder, that is, when it occurs in Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease, and similar disorders, more severe systemic symptoms (liver dysfunction, neurodegeneration, retinal abnormalities, hearing abnormalities, adrenal dysfunction, skeletal abnormalities) appear. In this case, elevated pipecolic acid serves as a marker of the peroxisomal disorder, and the clinical symptoms are caused by peroxisomal dysfunction.

α-Ketoadipic acidemia: cases with hypotonia, intellectual disability, delayed language development, and seizures have been reported. Because the disease is rare, the full spectrum of its clinical course is not known. Urinary excretion of α-ketoadipic acid, α-aminoadipic acid, and glutaric acid is increased.


7. Signs

The main laboratory findings and physical signs of lysine and hydroxylysine metabolism disorders are as follows.

Plasma amino acid abnormalities: marked elevation of plasma lysine in hyperlysinemia (more than 3 times normal). Simultaneous elevation of plasma lysine and saccharopine in hypersaccharopinemia. Elevated plasma hydroxylysine in hydroxylysinemia. Elevated plasma α-aminoadipic acid in α-ketoadipic acidemia.

Urine amino acid and organic acid abnormalities: elevated urine lysine and saccharopine in hyperlysinemia. Elevated urine pipecolic acid in pipecolic acidemia. Elevated urine α-ketoadipic acid, α-aminoadipic acid, and glutaric acid in α-ketoadipic acidemia. Urine organic acid GC-MS analysis is the key diagnostic tool.

Tandem MS/MS plasma acylcarnitines: hyperlysinemia itself causes no acylcarnitine abnormalities, but mild abnormalities may be observed in α-ketoadipic acidemia. Differentiation from GCDH deficiency (GA1) is required (C5DC is elevated in GA1).

Peroxisomal biochemical tests: when pipecolic acid is elevated, plasma very-long-chain fatty acids (VLCFA: C26:0, C26:1, C24:0/C22:0 ratio), phytanic acid, pristanic acid, red blood cell plasmalogens, and urine pipecolic acid are measured together to differentiate peroxisomal disorders. Elevated VLCFA and reduced plasmalogens strongly suggest a peroxisomal spectrum disorder.

Physical findings: no specific physical findings in asymptomatic patients with hyperlysinemia or hydroxylysinemia. In peroxisomal disorders accompanying pipecolic acidemia, hepatomegaly, severe hypotonia, facial dysmorphism, brain MRI abnormalities (leukodystrophy), and ophthalmic abnormalities (retinal abnormalities) are observed. Hypotonia, developmental delay, and seizures appear in α-ketoadipic acidemia.


8. Screening

Early detection of lysine and hydroxylysine metabolism disorders is achieved mainly through newborn tandem MS/MS screening and biochemical testing prompted by clinical suspicion.

Newborn tandem MS/MS screening: hyperlysinemia is sometimes detected incidentally when blood lysine is elevated on tandem MS/MS. However, lysine measurement is not included as standard in all newborn screening panels, and even where it is included, sensitivity varies because of differences in screening cutoffs. In addition, because hyperlysinemia is clinically asymptomatic in most cases, the clinical benefit of screening is under debate.

Urine organic acid and amino acid analysis: when there is clinical suspicion (intellectual disability, hypotonia, nonspecific developmental delay), lysine, saccharopine, pipecolic acid, α-ketoadipic acid, and α-aminoadipic acid are measured by urine organic acid analysis (GC-MS), and plasma amino acid chromatography is performed. If elevated pipecolic acid is found, peroxisomal biochemical testing is performed promptly in parallel.

Family screening: plasma amino acid analysis and genetic testing are performed in siblings of confirmed patients. Each parent is a heterozygous carrier without clinical symptoms. For disorders judged to have a benign course, excessive family screening may cause unnecessary concern, so it should be approached cautiously.


9. Diagnosis

Diagnosis of lysine and hydroxylysine metabolism disorders is made by biochemical metabolic analysis and molecular genetic confirmation.

Plasma amino acid analysis: elevated plasma lysine (hyperlysinemia), elevated plasma hydroxylysine (hydroxylysinemia), and elevated plasma α-aminoadipic acid (α-ketoadipic acidemia) are the key biochemical findings of each disorder. In hypersaccharopinemia, plasma saccharopine is elevated.

Urine organic acid analysis (GC-MS): lysine, saccharopine, pipecolic acid, α-ketoadipic acid, and α-aminoadipic acid are quantified in urine. Elevated urine α-ketoadipic acid and glutaric acid are characteristic of α-ketoadipic acidemia. When pipecolic acid is elevated, tests to differentiate peroxisomal abnormalities are added.

Enzyme activity measurement: AASS (LKR, SDH) enzyme activity is measured in liver tissue or cultured skin fibroblasts. Picolinic acid oxidase (PIPOX) activity is measured in red blood cells or liver tissue. When enzyme measurement is technically difficult, it is replaced by genetic testing.

Molecular genetic confirmation: pathogenic variants are identified by NGS of an AASS, AGXT2L1, PIPOX, and DHTKD1 gene panel. After a variant is identified, it is used for family counseling and planning of prenatal diagnosis. In patients with pipecolic acidemia, testing of the PEX gene family (related to peroxisome biogenesis) in addition to PIPOX is also needed.

Peroxisomal biochemical tests: when pipecolic acid is elevated, plasma very-long-chain fatty acids (VLCFA), phytanic acid, and red blood cell plasmalogens are tested to exclude Zellweger spectrum disorders. If these tests are normal, isolated pipecolic acidemia is considered.


10. Treatment

Treatment of lysine and hydroxylysine metabolism disorders differs by disorder, and in most cases no specific treatment has been established.

Hyperlysinemia (AASS deficiency): specific treatment is not recommended when the patient is clinically asymptomatic. A low-lysine diet (lysine restriction) can lower blood lysine, but evidence for preventing or improving clinical symptoms is insufficient. Because excessive lysine restriction can adversely affect protein synthesis and growth, it is not undertaken without specialist judgment. When seizures are present, standard anticonvulsants are used, and it must be determined whether the seizures are due to the lysine metabolic abnormality or to an independent cause. Patients with hyperlysinemia detected on newborn screening are followed together with a metabolic specialist and monitored for the development of clinical symptoms.

Hydroxylysinemia: because it is clinically asymptomatic, no specific treatment is needed. Follow-up after diagnosis is recommended. Collagen abnormalities may be a concern, but there is no evidence for this, so no special restrictions are needed.

α-Ketoadipic acidemia: a low-lysine, low-tryptophan diet (low-protein diet) may reduce α-ketoadipic acid production. There are individual case reports of symptomatic improvement with riboflavin (vitamin B2) supplementation in some patients. α-Ketoadipic acid dehydrogenase is FAD-dependent, and riboflavin acts as a cofactor. Seizures are treated with standard anticonvulsants. Rehabilitation such as physical therapy and speech therapy is provided for hypotonia and developmental delay.

Pipecolic acidemia: no specific treatment has been established for isolated pipecolic acidemia. When it accompanies a peroxisomal spectrum disorder, the treatment guidelines for that disorder (dietary management, supportive care) are followed. Docosahexaenoic acid (DHA) supplementation has been tried in some peroxisomal disorders.


11. Prognosis

The prognosis of lysine and hydroxylysine metabolism disorders varies greatly depending on the type of disorder and whether accompanying peroxisomal abnormalities are present.

Prognosis of hyperlysinemia: prognosis is good in most cases. Long-term follow-up studies of patients with hyperlysinemia detected by newborn screening have frequently reported no significant neurodevelopmental difference compared with the general population. Hyperlysinemia is therefore now strongly regarded as a benign metabolic abnormality. Because excessive therapeutic intervention may actually harm growth and development, observation is the main management approach. Even if nonspecific neurodevelopmental abnormalities occur in some patients, they are more likely due to an accompanying independent cause than to hyperlysinemia itself.

Prognosis of hydroxylysinemia: because it is clinically asymptomatic with a benign course, the prognosis is very good. Routine follow-up is sufficient.

Prognosis of pipecolic acidemia: data on the long-term prognosis of isolated pipecolic acidemia are lacking. When accompanied by a peroxisomal spectrum disorder (Zellweger syndrome), the prognosis is poor, with progression of severe neurodegeneration, visual and hearing impairment, and liver failure. In severe Zellweger syndrome, survival is very short, usually within 1 year.

Prognosis of α-ketoadipic acidemia: very few cases have been reported, so long-term natural history data are lacking. Intellectual disability and developmental delay persist in some cases, but improvement with treatment (low-protein diet, riboflavin) has also been reported. Overall, prognostic data are insufficient, making it difficult to judge prognosis in individual patients.


12. Prevention

Prevention of lysine and hydroxylysine metabolism disorders differs by disorder; because the clinical significance of most is unclear, follow-up takes priority over prevention.

Newborn screening and follow-up: when abnormalities of lysine or related metabolites are found on tandem MS/MS newborn screening, prompt confirmatory testing and referral to a metabolic specialist are recommended. Since the clinical significance of hyperlysinemia is currently unclear, regular follow-up (neurodevelopmental assessment, plasma lysine measurement, imaging if needed) rather than unnecessary therapeutic intervention is the main management. When elevated pipecolic acid is found, prompt testing to differentiate peroxisomal spectrum disorders is essential.

Importance of differentiating peroxisomal disorders: when pipecolic acidemia is suspected, Zellweger syndrome spectrum disorders must be excluded first. Because this group of disorders involves severe multiorgan involvement and a poor prognosis, rapid diagnosis and supportive care are important. Very-long-chain fatty acid (VLCFA), phytanic acid, and plasmalogen tests are performed early.

Genetic counseling and family screening: the parents of a confirmed patient are each carriers, and siblings have a 25% risk of being affected. In subsequent pregnancies, prenatal diagnosis (CVS, amniocentesis) or preimplantation genetic testing (PGT) is considered. In clinically asymptomatic cases such as hyperlysinemia, thorough counseling on the clinical benefit of prenatal diagnosis is needed. In genetic counseling, the uncertainty of clinical significance is fully explained to caregivers.

Dietary guidance: in α-ketoadipic acidemia, a low-protein diet restricted in lysine and tryptophan may lower metabolite levels. An individualized dietary plan is established under the guidance of a specialist metabolic dietitian, taking care that essential amino acid deficiency does not occur. Growth is monitored in parallel to prevent nutritional deficiency.


13. References

  1. Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases: Diagnosis and Treatment. 6th ed. Berlin: Springer; 2016. ISBN: 978-3-662-49771-5.

  2. Danhauser K, Sauer SW, Haack TB, et al. DHTKD1 mutations cause 2-aminoadipic and 2-oxoadipic aciduria. Am J Hum Genet. 2012;91(6):1082-1087. DOI: 10.1016/j.ajhg.2012.10.006. PMID: 23141293.

  3. Houten SM, Te Brinke H, Denis S, et al. Genetic basis of hyperlysinemia. Orphanet J Rare Dis. 2013;8:57. DOI: 10.1186/1750-1172-8-57. PMID: 23570596.

  4. Ghadimi H, Binnington VI, Pecora P. Hyperlysinemia associated with retardation. N Engl J Med. 1964;273:723-729. DOI: 10.1056/NEJM196510072731402. PMID: 5843069.

  5. Fischer MH, Gerritsen T, Opitz JM. Alpha-aminoadipic aciduria, a non-deleterious inborn metabolic defect. Humangenetik. 1974;24(4):265-270. DOI: 10.1007/BF00289022. PMID: 4456124.

  6. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem. 2006;75:295-332. DOI: 10.1146/annurev.biochem.74.082803.133329. PMID: 16756494.

  7. Struys EA. 2-Hydroxyglutarate is not a metabolite; D-2-hydroxyglutarate and L-2-hydroxyglutarate are! Proc Natl Acad Sci USA. 2013;110(51):E4939. DOI: 10.1073/pnas.1318501110. PMID: 24307568.

  8. Kölker S, Cazorla AG, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38(6):1041-1057. DOI: 10.1007/s10545-015-9839-3. PMID: 25875215.

  9. Christensen E. Pipecolic acid and hydroxylysine in hyperlysinemia. J Inherit Metab Dis. 1981;4(4):231-232. DOI: 10.1007/BF02263655. PMID: 6799050.

  10. Lee HJ, Yoo HW, Choi JY, et al. Expanded newborn screening by tandem mass spectrometry in Korea. J Inherit Metab Dis. 2008;31 Suppl 2:S299-S304. DOI: 10.1007/s10545-008-0921-5. PMID: 18615329.